Overview
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.
Description
This study will enroll patients with wet age-related macular degeneration (wAMD) who have previously be treated with EXG102-031 injection, those patients will Voluntary join this long-term follow-up study to be evaluated the long-term safety and efficacy.
The first two years of long-term follow-up will be conducted every 2 months; From 3 years to 5 years after administration,follow-up visits will be conducted every six months.
Eligibility
Inclusion Criteria:
- Previously received treatment with EXG102-031 in the study (EXG102-031-111);
- Paticipantes are informed consent and willingness to follow protocol procedures.
Exclusion Criteria:
- Paticipantes are unwilling or unable to participate in long-term follow-up